At a glance
- Originator Tanabe Seiyaku
- Class
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Erectile dysfunction
Most Recent Events
- 09 Dec 2003 No development reported - Preclinical for Erectile dysfunction in Japan (unspecified route)
- 29 Mar 2001 New profile
- 29 Mar 2001 Preclinical development for Erectile dysfunction in Japan (Unknown route)